AI brief of an SEC Form 8-K · Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia Q2 revenue rises 19% to $83.2 million; net income up 74% to $37.4 million

Positive Impact 3 of 5 earnings Written later

Aurinia reported second-quarter 2026 total revenue of $83.2 million, up 19% from a year earlier, with net income of $37.4 million and diluted EPS of $0.28, both up sharply from the prior-year quarter. The company reiterated its 2026 total revenue guidance of $315 million to $325 million, so the headline results improved and the outlook was unchanged.

Key points

  • Q2 2026 total revenue was $83.2 million, up 19% from $70.0 million; net product sales of LUPKYNIS were $79.4 million.
  • Q2 2026 net income was $37.4 million, up 74% from $21.5 million; diluted EPS was $0.28 versus $0.16.
  • 2026 guidance reiterated: total revenue of $315 million to $325 million and net product sales of $305 million to $315 million.
  • In the six months ended June 30, 2026, Aurinia repurchased 5.0 million common shares for $74.9 million; cash and investments were $443.1 million at June 30, 2026.

The filing

CompanyAurinia Pharmaceuticals Inc. (AUPH)
Form8-K, current report
Filed with the SECAug 6, 2026, 8:03 AM ET
Accession number0001600620-26-000059

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.